13F reference period
Q2 2026
Security Snapshot
Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO) Institutional Ownership
CUSIP: 98422T100
13F Institutional Holders and Ownership History from Q4 2021 to Q2 2026
Institutions Reporting
1
Shares (Excl. Options)
650.39K
Full value: 650,389 · shares · 30 Jun 2026Price
$9.58
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Symbol
- XLO on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 650,389
- Total 13F value
- $6,230,727
- Share change
- 0
- Number of holders
- 1
- Shares outstanding
- 6,426,426
- SEC-reported price per share
- $9.58
- Insider filing price
- $9.58
Latest holder snapshot
3 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- XLO - Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 98422T100.
- 1 institution reported positions in Q2 2026.
- 8 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 1 to 1 between Q1 2026 and Q2 2026.
- SEC-reported value moved from to
$5.47M
Full value: $5,469,771 · USD · 31 Mar 2026.$6.23M
Full value: $6,230,727 · USD · 30 Jun 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 1 institution filings for Q2 2026.
Security key
98422T100
13F reference period
Q2 2026
13F holders
1
13D/G owners
8
CIK / CUSIP context first
Open Q2 2026 holders
XLO full holder history
Xilio Therapeutics, Inc. SEC filings
Xilio Therapeutics, Inc. company facts
Xilio Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 98422T100:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
8
Security
XLO
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| GILEAD SCIENCES, INC. | 20% | 0% | $9,581,667 | +$2,576,464 | 14,517,678 | +37% | GILEAD SCIENCES, INC. | 31 Dec 2025 |
| STEMPOINT CAPITAL LP | 8.4% | +17% | $3,979,818 | +$1,339,818 | 6,030,028 | +51% | StemPoint Capital LP | 31 Dec 2025 |
| Coastlands Capital LP | 10% | $3,742,248 | 5,346,069 | Coastlands Capital LP | 04 Dec 2025 | |||
| Frazier Life Sciences Public Fund, L.P. | 6.7% | -32% | $3,086,472 | -$2,286,600 | 4,676,472 | -43% | Frazier Life Sciences Public Fund, L.P. | 31 Dec 2025 |
| AbbVie Inc. | 9% | $3,304,348 | 4,347,826 | AbbVie Inc. | 11 Feb 2025 | |||
| Sirenia Capital Management LP | 9.9% | $9,611,469 | 1,142,862 | Sirenia Capital Management LP | 31 Mar 2026 | |||
| Bain Capital Life Sciences Fund II, L.P. | 10% | +17% | $5,584,417 | -$47,060,014 | 664,021 | -89% | BCLS II Equity Opportunities, LP | 31 Mar 2026 |
| ORBIMED ADVISORS LLC | 10% | $5,399,220 | 642,000 | ORBIMED ADVISORS LLC | 31 Mar 2026 |
As of 30 Jun 2026,
1
institutional investors reported holding
shares of
Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO).
This represents
10%
of the company’s total
outstanding shares.
650.39K
Full value: 650,389 · shares · 30 Jun 20266.43M
Full value: 6,426,426 · shares · Stored outstanding share count13F concentration
Top 1 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
10%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| GILEAD SCIENCES, INC. | 10% | 650,389 | 0% | 0.38% | $6,230,727 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
19
Headline period
Q2 2026
Rows shown
1-19 of 19
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 650,389 | $6,230,727 | $9.58 | 1 | |
| 2026 Q1 | 650,389 | $5,469,771 | -$89,907,489 | $8.41 | 1 |
| 2025 Q4 | 39,727,815 | $25,433,377 | +$11,324,174 | $0.64 | 37 |
| 2025 Q3 | 22,051,916 | $18,613,906 | -$1,227,318 | $0.84 | 36 |
| 2025 Q2 | 23,795,263 | $16,179,092 | +$854,217 | $0.68 | 35 |
| 2025 Q1 | 22,528,206 | $16,318,555 | -$3,181,066 | $0.72 | 35 |
| 2024 Q4 | 25,814,355 | $24,660,128 | -$144,644 | $0.96 | 34 |
| 2024 Q3 | 15,911,945 | $12,534,583 | +$1,128,156 | $0.79 | 32 |
| 2024 Q2 | 14,508,823 | $13,746,216 | +$1,785,264 | $0.95 | 31 |
| 2024 Q1 | 12,460,895 | $13,460,257 | -$2,676,053 | $1.08 | 30 |
| 2023 Q4 | 16,426,281 | $9,034,716 | -$1,543,598 | $0.55 | 33 |
| 2023 Q3 | 15,860,160 | $33,465,952 | -$314,935 | $2.11 | 30 |
| 2023 Q2 | 16,002,286 | $41,925,598 | -$192,245 | $2.62 | 32 |
| 2023 Q1 | 16,072,057 | $50,979,505 | +$461,644 | $3.17 | 32 |
| 2022 Q4 | 15,926,513 | $42,841,966 | -$709,927 | $2.69 | 28 |
| 2022 Q3 | 16,606,568 | $48,328,000 | -$3,750,524 | $2.91 | 28 |
| 2022 Q2 | 17,880,380 | $52,211,910 | -$3,647,986 | $2.92 | 29 |
| 2022 Q1 | 18,775,939 | $132,746,000 | -$2,569,332 | $7.07 | 41 |
| 2021 Q4 | 18,324,586 | $269,421,063 | +$225,248,000 | $16.00 | 41 |